Figure 3.

(A) Histology of spleen (i), bone marrow (ii), lung (iii), and liver (iv) from control HL-60-injected mice day 21 postleukemia inoculation. (i) Note a massive tumor infiltrate (arrow) in the spleen of these mice. The bone marrow (ii) has evidence of increased angiogenesis and is largely replaced by tumor cells. Finally, the lungs of these mice were largely replaced by tumor cells (iii), and the liver showed extensive areas of invading tumor cells (iv). (Magnifications: i–iii, ×; iv, ×400.) (B) Histology of livers (i, ii, and iv–ix) and spleen (iii) of HL-60-inoculated, antibody-treated mice. DC101-treated mice, day 21 postinoculation, had some sign of leukemic infiltrates in the liver (arrow, i and ii) and the spleen was largely replaced by tumor cells (iii). On the other hand, in IMC-1C11-treated mice tumor infiltration was localized to the perivascular area of the liver on days 21 and 42 (iv–vi). Finally, IMC-1C11 + DC101-treated mice had no evidence of metastatic disease on days 21 and 42 (vii and viii) but one small micrometastasis could be detected on day 60 (ix). (Magnifications: i, iii, iv, v, vii, viii, and ix, ×200; ii and vi, ×400.)